Beeline Medicines

Clinical Trials

Our Current Clinical Trials

DISCOVERY

Lupus affects more than your skin.
Every DISCOVERY towards progress matters.

The DISCOVERY study (NCT07881120) is a global Phase 2/3 clinical trial evaluating afimetoran in people living with cutaneous lupus erythematosus (CLE). It is a two-stage, randomized, double-blind, placebo-controlled, multi-center trial evaluating the efficacy and safety of afimetoran in adults with active CLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.

The safety and effectiveness of afimetoran have not yet been established.

To learn more about the DISCOVERY study, visit clinicaltrials.gov or email [email protected].

Participants may qualify for the DISCOVERY study if they:

  • Are 18 years of age or older (or 16 years of age or older where permitted).
  • Have a physician's diagnosis of cutaneous lupus erythematosus (CLE), with or without lupus affecting other parts of the body.
  • Have active lupus rashes or sores on the skin.
  • Have taken hydroxychloroquine (Plaquenil), an antimalarial medicine, without sufficient improvement, or were unable to take it.

Additional eligibility criteria apply.

Investigational Development Candidate:
Afimetoran

Condition:
Cutaneous Lupus Erythematosus (CLE)

Trial Phase:
Phase 2/3

Living with Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE) is a chronic, lifelong autoimmune disease that affects the skin. It can cause rashes, sores, changes in skin color, scarring, and other visible symptoms that may change over time and that may appear in one area or across different parts of the body. Some people have CLE on its own, while others may have another form of lupus as well. CLE is estimated to affect approximately 70 out of every 100,000 people in the United States and Europe. It is more common in women than in men and occurs more often in people of Black, Hispanic, Asian, and Indigenous ancestry.1-4

The impact of CLE can go well beyond the skin. For some people, especially those with a type of CLE called discoid lupus, repeated flares can lead to permanent scarring or changes in skin color. Because these symptoms can be highly visible and flares can be unpredictable, living with CLE can affect daily routines, social activities, work, emotional well-being, and quality of life.

There is still more to understand, and progress starts with research and the people willing to take part. Whether you’re living with lupus, caring for someone who is, or simply interested in clinical research, you can learn more about our current studies and how participation can contribute to advancing what we know about CLE.

References:

  1. Elmgren J, Nyberg F. Front Med (Lausanne). 2023;9:984229.
  2. Stull C et al.Stull C et al. J Rheumatol. 2023;50(1):27–35.
  3. Joseph AK et al. Lupus Sci Med. 2021;8(1):e000514.
  4. Merola JF et al. Front Med (Lausanne). 2024;11:137552.